Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-11180540-B2
Application number	US-202016996127-A
Country	US
Kind code	B2
Filing date	Aug 18, 2020
Priority date	Dec 6, 2019
Publication date	Nov 23, 2021
Grant date	Nov 23, 2021

Abstract

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.

First claim

What is claimed is:

1. A method of producing aflibercept MiniTrap from a clarified harvest of a cell cultured in a chemically defined medium (CDM) and expressing aflibercept, comprising:
(a) binding aflibercept from said clarified harvest to a first capture chromatography;
(b) eluting said aflibercept of step (a) and subjecting said aflibercept to enzymatic cleavage to remove its Fc domain thereby forming MiniTrap;
(c) subjecting (b) to a second capture chromatography, wherein said second capture chromatography step is subjected to one or more washes, and wherein a first flowthrough fraction comprises MiniTrap and has a first color, wherein said first color has a b* value ranging from 1.5 to 15.0 when protein concentration is normalized to 5.0 g/L;
(d) subjecting said first flowthrough fraction of step (c) to anion exchange chromatography (AEX); and
(e) washing said AEX column of step (d), wherein said MiniTrap is collected in a second flowthrough fraction and has a second color, wherein said second color has a b* value ranging from 0.5 to 15.0 when protein concentration is normalized to 5.0 g/L and wherein said first color is a more intense yellow brown color than said second color.

2. The method of claim 1 , wherein said both first and second capture chromatography comprises Protein A resin.

3. The method of claim 1 , wherein said cell is selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

4. The method of claim 1 , wherein said clarified harvest comprises one or more aflibercept variants, wherein said variants have at least one oxidized amino acid residue.

5. The method of claim 4 , wherein said oxidized amino acid residue is selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

6. The method of claim 5 , wherein said oxidized amino acid residue is histidine.

7. The method of claim 5 , wherein said oxidized amino acid residue is tryptophan.

8. The method of claim 4 , wherein said aflibercept variant comprises a peptide with an amino acid sequence selected from the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, SEQ ID NO.: 62, SEQ ID NO.: 63, SEQ ID NO.: 64, SEQ ID NO.: 65, SEQ ID NO.: 66, SEQ ID NO.: 67, SEQ ID NO.: 68, SEQ ID NO.: 69, SEQ ID NO.: 70, SEQ ID NO.: 71 and combinations thereof.

9. The method of claim 1 , wherein said AEX column comprises an anionic exchange substituent including diethylaminoethyl (DEAE), quaternary aminoethyl (QAE) and quaternary amine (Q) groups.

10. The method of claim 1 , further comprising after clarified harvest, subjecting aflibercept to one or more further chromatographic steps selected from the group consisting of: cation exchange chromatography, hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

11. A method of producing aflibercept MiniTrap from a clarified harvest of a cell cultured in a chemically defined medium (CDM), comprising:
(a) binding aflibercept from said clarified harvest to a first capture chromatography;
(b) eluting said aflibercept of step (a) and subjecting said aflibercept to enzymatic cleavage to remove its Fc domain thereby forming MiniTrap;
(c) subjecting (b) to a second capture chromatography, wherein said second capture chromatography step is subjected to one or more washes, and wherein a first flowthrough fraction comprises MiniTrap, wherein said MiniTrap has one or more acidic species;
(d) subjecting said first flowthrough fraction of step (c) to anion exchange chromatography (AEX); and
(e) washing said AEX column of step (d) and collecting in a second flowthrough fraction, wherein the percent of acidic species of MiniTrap in said affinity eluate of step (b) is greater than the percent of acidic species of MiniTrap in said AEX second flowthrough fraction when concentration of protein in said eluate and AEX flowthrough fraction are normalized, wherein said acidic species of MiniTrap correspond to the peaks that elute earlier than the main peak in a strong cation exchange chromatography (CEX) chromatogram of aflibercept, and wherein a chromatogram is generated using a first mobile phase of 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.7 and a second mobile phase of 40 mM sodium phosphate, 100 mM sodium chloride pH 9.0 (Mobile phase B), and wherein a chromatogram is generated using detection at 280 nm.

12. The method of claim 11 , wherein said both first and second capture chromatography comprises Protein A resin.

13. The method of claim 11 , wherein said AEX flowthrough fractions comprises less than 20% total acidic species of MiniTrap.

14. The method of claim 11 , wherein said acidic species of MiniTrap comprises at least one oxidized amino acid residue selected from group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

15. The method of claim 11 , wherein the pH of both said equilibration and wash buffers for said AEX column are from 8.30 to 8.60.

16. The method of claim 11 , wherein the conductivity of both said equilibration and wash buffers for said AEX column can be from 1.50 to 3.0 mS/cm.

17. The method of claim 11 , wherein the enzymatic cleavage to remove the Fc domain from aflibercept to generate MiniTrap uses proteolytic digestion employing a protease or an enzymatically active variant thereof.

18. The method of claim 17 , wherein said protease is an immunoglobulin-degrading enzyme of Streptococcus pyogenes (IdeS).

19. The method of claim 11 , further comprising after binding aflibercept from said clarified harvest, subjecting aflibercept to one or more further chromatographic steps selected from the group consisting of: cation exchange chromatography (CEX), hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

20. A method of producing MiniTrap from a clarified harvest of a cell cultured in a chemically defined medium (CDM), comprising:
(a) binding aflibercept from said clarified harvest to a Protein A resin;
(b) eluting said aflibercept of step (a) and subjecting said aflibercept to enzymatic cleavage to remove its Fc domain thereby forming MiniTrap;
(c) subjecting (b) to a second capture chromatography, wherein said second capture chromatography step is subjected to one or more washes, and wherein a first flowthrough fraction comprises MiniTrap, wherein said MiniTrap has one or more oxidized species of MiniTrap;
(d) subjecting said first flowthrough fraction of step (c) to anion exchange chromatography (AEX); and
(e) washing said AEX column of step (d) to obtain a second flowthrough fraction, wherein the percent of oxidized species of MiniTrap in said affinity eluate of step (b) is greater than the percent of oxidized species in said AEX second flowthrough fraction when the concentration protein in said eluate and flowthrough fraction are normalized, and wherein said oxidized species of MiniTrap is measured by subjecting said affinity eluate and said flowthrough fractions to digestion, followed by their analysis using reverse-phase ultra-performance chromatography (UPLC), detection at wavelengths of 280 nm, 320 nm and 350 nm and mass spectrometry analysis using a first mobile phase of 0.1% formic acid in water and a second mobile phase of 0.1% formic acid in acetonitrile.

21. The method of claim 20 , wherein said oxidized amino acid residue is selected from group consisting of m

Assignees

• Regeneron Pharma

Inventors

• Tustian Andrew
• Vartak Ankit
• Daly Thomas
• Pyles Erica
• Palackal Nisha
• Wang Shunhai
• Li Ning
• Franklin Matthew

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title